IFNB1 and myeloid sarcoma: This study demonstrated a high likelihood, up to 16.7 %, of detecting disease activity in clinically stable MS patients being treated with IFN-B or GA, in a community-based cohort in which routine MRI scanning was performed on a yearly basis.